
End-to-End Reward Decomposition and Explainable Interaction: A Medical Inverse Reinforcement Learning Framework

Lian
AI Thrust, Info Hub, HKUST(GZ)
xlian289@connect.hkust-gz.edu.cn

Introduction



Problem Statement:

- Patient Profile: 65 year old male admitted with diabetes, chronic kidney disease, and heart failure simultaneously.
- Treatment Dilemma
 - Doctors need to balance treatment effectiveness for all three diseases.
 - Must avoid drug conflicts and adverse reactions.
- Data and Interaction Issues
 - Incomplete records of disease progression.
 - Dynamic, complex interactions between the three conditions over time.

Research Motivation:

- How can we clearly decompose and explain multiple clinical objectives in complex medical decisions?
- How can we robustly complete and utilize patient data when observations are missing or incomplete?
- How can we make every step of AI-driven medical decisions fully transparent and traceable for clinicians?

Related Work

| Research Direction | Recent Representative Works & References | Main Advances | Limitations & Challenges | |
|---|---|---|--|--|
| Inverse Reinforcement Learning (IRL) in Healthcare | - Jayaraman & Desman, 2024 (Nat. Digital Med.): Federated IRL - Snoswell et al., 2024 (Front. Digital Health): Telemedicine preference IRL - Fang et al., 2024 (arXiv): Safe clinical IRL | Enables personalized medical recommendations Addresses privacy via federated learning Models patient preferences for telehealth | Assumes complete data Struggles with complex multimorbidity interactions Limited reward interpretability | |
| Causal Modeling for Multimorbidity | Langenberg et al., 2023 (Nat. Medicine): Multimorbidity causal framework Yin et al., 2025 (arXiv): Multiagent RL for disease interaction | Reveals disease progression patterns Captures dynamic interactions between multiple diseases | Difficult to disentangle temporal causal effects Lacks real-time, individualized decision support | |
| Learning from Partially Observed Data | - Liu et al., 2024 (ICLR): POMDP and inverse weighting - Xia et al., 2024 (OpenReview): Contrastive learning for EHR | Adapts to incomplete medical records Utilizes partial data effectively through contrastive learning | Uncertaintyquantification issuesLimited theoreticalguarantees forconvergence | |
| Optimization of Multimorbidity Treatment Decisions | - Zhang et al., 2024 (AAAI): Multi-task RL for comorbidity - Tan et al., 2024 (arXiv): Hierarchical multi-agent RL for multi-organ care | | | |


• IRL on incomplete, real-world multimorbidity data.

 Causal disentanglement of dynamic disease interactions.

Robust learning under partial observation and uncertainty.

Temporal conflict detection and multi-objective optimization.

Methodology



Core Technical Innovations

Transparent Reward Decomposition

- Breaks complex clinical goals into clear, independent components.
- Orthogonality and attention ensure each reward is clinically meaningful and explainable.

•

Robust Trajectory Completion

- Fills in missing patient data using a hybrid of deep learning and medical knowledge.
- Guarantees reliable, realistic recovery even with high data gaps.

Full-Path Explainability

- Visualizes every step of AI decision-making across time, features, and strategy.
- Empowers clinicians with dynamic, interactive, and traceable insights.

$$R(s,a) = \sum_{i=1}^{K} w_i(s) \cdot r_i(s,a), \quad L_{ortho} = \sum_{i
eq j} |r_i^T r_j|$$

 $L = ext{ELBO} + lpha \cdot KG_{Loss} + eta \cdot Temporal_Smoothness$



Experimental Results

1 Method Comparison

Table 1: Comparison of Different Methods

| Method | Components | | | | | |
|-----------|----------------|------------------|----------------|---------|--|--|
| | Reward Decomp. | Trajectory Comp. | Medical Align. | Visual. | | |
| MERIT-IRL | ✓ | × | × | × | | |
| XAI-Med | ✓ | × | ✓ | 1 | | |
| PO-IRL | × | ✓ | × | × | | |
| LRD-IIRL | ✓ | ✓ | ✓ | ✓ | | |

2 Quantitative Results

Table 2: Quantitative Results on MIMIC-IV Dataset

| Method | Reward Reconstruction | | | Traj. Acc | Med. Rel |
|-----------|-----------------------|--------|------------|------------|----------|
| | MSE | RMSE | Rel. Error | Traj. Tree | Mod. Ho. |
| MERIT-IRL | 0.9951 | 0.9975 | 0.9951 | 0.0049 | 0.80 |
| XAI-Med | 0.9932 | 0.9966 | 0.9932 | 0.0068 | 0.85 |
| PO-IRL | 1.0023 | 1.0011 | 1.0023 | -0.0023 | 0.75 |
| LRD-IIRL | 0.9812 | 0.9905 | 0.9812 | 0.0068 | 0.87 |

6 Evaluation Metrics

Table 6: Evaluation Metrics Definition

| Metric | Calculation | Clinical Meaning |
|--|---|--|
| Reward Error Traj. Acc Med. Rel Δ SOFA | $\frac{\frac{1}{n} \sum_{i=1}^{n} (r_i - \hat{r}_i)^2}{\frac{1}{n} \sum_{i=1}^{n} \mathbb{I}(s_i = \hat{s}_i)} $ $\frac{1}{n} \sum_{i=1}^{n} \sin(c_i, \hat{c}_i) $ SOFA _{t+1} - SOFA _t | Treatment effect prediction State prediction accuracy Concept alignment degree Safety indicator |

3 Ablation Study

Table 3: Ablation Study Results

| Config. | Performance Metrics | | | ΔSOFA |
|-----------------|---------------------|-----------|----------|-------|
| comig. | Reward Err. | Traj. Acc | Med. Rel | |
| Full Model | 0.9812 | 0.0068 | 0.87 | 0.41 |
| w/o Dyn. Reward | 0.9935 | 0.0055 | 0.85 | 0.38 |
| w/o Variational | 0.9878 | 0.0042 | 0.86 | 0.39 |
| w/o Med. Align | 0.9966 | 0.0059 | 0.82 | 0.36 |
| w/o Attention | 0.9914 | 0.0060 | 0.84 | 0.37 |


4 Clinical Evaluation

Table 4: Clinical Evaluation Results

| Scenario | Expert Ratings | | | Acc. Rate |
|-----------------|----------------|-------------|-------------|-------------|
| Sections | Treatment | Interp. | Usability | 1100. 14400 |
| ICU Multi-morb. | 4.7 ± 0.3 | 4.5 ± 0.4 | 4.6 ± 0.3 | 92% |
| Oncology | 4.5 ± 0.4 | 4.3 ± 0.5 | 4.4 ± 0.4 | 88% |
| Emergency | 4.3 ± 0.5 | 4.2 ± 0.6 | 4.3 ± 0.5 | 85% |

0.996 0.994 0.994 0.992 0.990 0.998 0.988 0.39 0.39 0.39


Reward Error vs. ASOFA by Ablation Config



Dataset Statistics

Table 5: Dataset Statistics

| Dataset | Sample Size | | | Miss. Rate |
|-----------|-------------|-------|-------|---------------|
| | Train | Val. | Test | . Miss. Itali |
| MIMIC-IV | 15,000 | 3,000 | 2,000 | 5.2% |
| Synthetic | 10,000 | 2,000 | 1,000 | 0.0% |



Interactive System Performance



Adaptation Scenario

Clinical Decision Support:

Assists physicians in developing safe and effective treatment plans for patients with complex conditions like diabetes with heart failure.

Preventive Medicine:


Identifies early warning signs of disease interactions, enabling proactive interventions before complications develop.

Clinical Research:

Provides insights into disease interactions and treatment efficacy, supporting new therapeutic approach development.

Personalized Medicine:

Adapts recommendations to patientspecific factors, including disease duration and severity patterns.



Conclusion

Technical Innovations

- We introduce LRD-IIRL, an end-to-end framework that unifies reward decomposition, robust trajectory completion, and full-path explainability for clinical decision-making.
- Our method leverages orthogonal constraints and medical knowledge to disentangle multi-objective rewards, ensuring clinical interpretability.
- A hybrid variational autoencoder and knowledge graph module enables reliable patient trajectory recovery, even with high missingness.

Empirical Validation

- Extensive experiments on large-scale clinical datasets (e.g., MIMIC-IV) show LRD-IIRL outperforms state-of-the-art baselines in reward reconstruction, trajectory completion, and medical relevance.
- The framework achieves higher expert acceptance rates, demonstrating its value for trustworthy, real-world medical AI deployment.
- LRD-IIRL sets a new standard for interpretable and robust AI in healthcare.

Clinical Trust and Transparency

- The five-dimensional XAI-Viz system delivers transparent, interactive visualizations across time, features, rewards, policy, and expert comparison.
- Every AI decision is traceable and clinically aligned, bridging the trust gap between clinicians and intelligent systems.
- Our approach empowers doctors to understand, validate, and refine AI recommendations in real-world scenarios.

Q&A

Lian
AI Thrust, Info Hub, HKUST(GZ)
xlian289@connect.hkust-gz.edu.cn